If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 26
A Phase II Study of the Efficacy and Pharmacogenomics of Cladribine-Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia
Protocol No
IIT-ATALLAH-CLAGM-AML
Categories
Treatment Free Remission After Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Treatment Free Remission After Asciminib plus Imatinib in CP-CML
Protocol No
HJKC3-0003
Categories
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non Hodgkin Lymphoma
A Phase 1b Study of Oral AS-1763 in Patients with CLL/SLL or NHL
Protocol No
CARNABIOSCIENCES-C1763102
Categories
A Phase II Trial of De-Escalated PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
A Phase 2 Trial of PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Allogenic HCT
Protocol No
IIT-ABEDIN-PTCY-RUX-GVHD
Categories
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Study of tandem, bispecific anti-CD19 anti-CD20 CAR-T cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Protocol No
IIT-SHAH-IL7-IL15-CD20-19
Categories
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Patients with Mature B-Cell Malignancies
A Phase 1 Study if SGR-1505 in Patients with B-Cell Malignancies
Protocol No
SCHRODINGER-SGR-1505-101
Categories
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
Venetoclax and Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL
Protocol No
ECOG-EA9152-ALL
Categories
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
This study is being done to answer the following question: Can we improve the chance of your leukemia going away (remission) and lower the chance of your leukemia coming back (relapsing) by adding an investigational drug called inotuzumab ozogamicin (hereafter, inotuzumab) to lower doses of the usual chemotherapy for acute lymphoblastic leukemia?
We are doing this study because we want to find out if this approach is better or worse than the
usual approach for your acute lymphoblastic leukemia. The usual approach is defined as care
most people get for acute lymphoblastic leukemia.
We are doing this study because we want to find out if this approach is better or worse than the
usual approach for your acute lymphoblastic leukemia. The usual approach is defined as care
most people get for acute lymphoblastic leukemia.
Protocol No
ALLIANCE-A042001
Categories
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Steroids plus TKI with Blinatumomab or Chemo for Newly Diagnosed BCR-ABL Positive ALL in Adults
Protocol No
ECOG-EA9181-ALL
Categories
BLAST MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML
What are the good and bad effects of adding the study drug pembrolizumab to the usual treatment for patients with chronic myelogenous leukemia (CML)? The usual approach is defined as care most people get for CML and includes treatment with tyrosine kinase inhibitors (TKIs).
Protocol No
ECOG-EA9171
Categories